TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: AUC for unbound drug (AUCu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient compliance with intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Goblet cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion progressing to respiratory failure or death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Postoperative Sorethroat
Endpoint domain: Adverse events/effects
Primary endpoint: Resident accuracy in identifying biopsy sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of swelling after orthognathic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Post-index Cardiovascular (CV) Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hazard Ratio for First Cardiovascular (CV) Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in urinary levels of porphobilinogen (PBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in urinary levels of delta-aminolevulinic acid (ALA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in the true diffusion coefficient (D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception during pneumococcal vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resection of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of GSK2857916
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of GSK2857916
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC over the dosing interval (AUC[0-tau]) of GSK2857916
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wellbeing Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Break-Up-Time (BUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of lung ultrasound scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes from baseline in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial load analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peri-implant pathologies development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Prolonged Air Leaks
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization of INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Months in Methadone Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Monthly Urine Sample Negative for Opiates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Monthly Urine Samples Negative for Cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Ankle Osteoarthritis Scale (AOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of patients without failure to the e-follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: agreement of NICOM and MRT cardiac output measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: precision of NICOM cardiac output measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 100 day (complete + partial) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Endocrine Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MoCA test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score of Cohen-Mansfield Agitation Inventory (CMAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in OFF time hours per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation in previously non-ventilated lung tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: System accuracy relative to ISO 15197 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Treatment Related Mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in Mitral Regurgitation (MR) grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of questionnaires with errors
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Depressive state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax - Maximum Observed Concentration - Oxcarbazepine in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Oxcarbazepine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Oxcarbazepine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Notification Rate Ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Costs Per Detected Case
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of completely healed ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of stent struts neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Hypotension and/or Bradycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of accidental awareness under general anaesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of SFA training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in Patient Health Questionnaire (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Metabolite Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: liver fat content (percent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fatty liver staging (0, I, II, and III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Qualifying Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Seizure Freedom, Defined as Engel Classification of Postoperative Outcome Class I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radiographic Bone Level Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Beck Depression Scale (BDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: C-Section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bone Mineral Density Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactulose-Mannitol Ratio (LMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discomfort threshold to rectal distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in QTcF interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Numerical Rating Scale (NRS) during needle manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Morbidity from hemorrhoidal surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood Folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine Folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of known genetic variants associated with nephrolithiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of RSV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Energy intake over 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Standardized uptake value of 68Ga-BBN-IRDye800CW
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse Events and Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of incisional hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ATIII activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduction of pro inflammatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative Pulmonary complications rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory muscles strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: New bone in contact with the implant surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hepatic function tests (ALT/AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Outcome (Global Assessment)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Plasma Concentration After Repeat Dosing of Umeclidinium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) After Repeat Dosing of Umeclidinium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time to Reach Cmax (Tmax) of Umeclidinium After Repeat Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reliever drugs usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With 50 Percent Improvement in PASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to adequate heart rate control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Embolization success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of emerging pathogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Progression Free Survival Rate at 9 Months
Endpoint domain: Mortality/survival
Primary endpoint: Prostate tissue content of DHT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of change in Trauma Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dyspnea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Death within 30 days after procedure
Endpoint domain: Mortality/survival
Primary endpoint: Change in Current Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Measure of energy cost during walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplant related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Acute and chronic GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Skin Prick Test to Common Allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Assessment of IgE-mediated Allergic Eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain response to heroin-related visual cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wrist Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in fruit, vegetable, whole grain intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caliber of Choroidal New Vessel (CNV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Clinical Evident Anastomotic Leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of participants changing from ESBL-positive to ESBL-negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Methylase status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in systolic and/or diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Randomized Patients With ≥80% Chronic Medication Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients Who Have the % Fetal Hemoglobin (%HbF) Collected at Baseline and at Study Exit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Interpretation Time of Scan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in FACIT-Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mammography Appointment Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean percent change in non-inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall satisfaction with surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life measured by EORTC-QLQc30 scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of mucosal biofilm formations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increment in diagnostic yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: side branch occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of genetics variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IQ
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in corneal endothelial cell density at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in coefficient of variation of cell size at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in corneal endothelial cell hexagonality at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in central corneal thickness at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of PEDIACEL® Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in total tic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wellness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence and grades of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Quit rate at the end of 1 year
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of comprehension of paragraph-level information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mother infant interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum Copper
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum Zinc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Haemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effective clinical treatment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure - Change From Baseline to End-of-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity - Change From Baseline to End-of-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Retention at 4 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant Retention at 8 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Measure participant satisfaction of the telehealth intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Classification of patients as alive with or without sequelae or death
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of patients experiencing treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of patients experiencing adverse events of special interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Performance status using Karnofsky performance status criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptom impairment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Viral Load < 400 Copies /mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Telehealth acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sum Common Toxicity Criteria score
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Common Toxicity Criteria score
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-free survival rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Level of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical laboratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events to induction standard therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Microbiological efficacy at Test of Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Functional recovery post-TKA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of the Percentage of spermatozoa presenting a fragmented DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Peripheral block score (PBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Changes in Brain Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Wrinkle Appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Change in Appearance of Skin Pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Concentration of fluoride in biofilm and nails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early post-surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Elasticity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elastography area ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBOT acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HBOT adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: composite of all-cause mortality
Endpoint domain: Mortality/survival